Explore Our Trials
Gateway for Cancer Research is one of the only nonprofits that exclusively funds innovative Phase I and Phase II cancer clinical trials for patients of all ages, regardless of cancer type. At the forefront of research and discovery, these early-phase trials are the first step in evaluating new cancer drugs, treatments, and therapies.
Results 31-40 of 47
Breast Cancer
The STOP-HER2 Study
The STOP-HER2 Study Summary: HER2 positive (HER2+) breast cancers account for 20-25% of breast cancers and are associated with higher rates of recurrence and brain metastases. However, in the past two decades, HER2 targeting therapies have drastically improved patient outcomes and most patients treated with stage I-III HER2+ breast cancer are cured. For patients with […]
Heather Parsons, MD, MPH
Dana-Farber Cancer Institute
Solid Tumors
Responder-derived FMT and anti-PD-1 in PD-1 refractory melanoma and NSCLC
Responder-derived FMT and anti-PD-1 in PD-1 refractory melanoma and NSCLC Summary: Cancer cells evolve and develop protective mechanisms to hide themselves from cancer killing T-cells. Immune checkpoint inhibitors (ICI), block these protective mechanisms by targeting PD-1/PD-L1 (or CTLA-4), unhiding cancer cells so that they can be killed by T-cells. While ICIs have become the standard […]
Diwakar Davar, MD, MSc
University of Pittsburgh
Breast Cancer
Phase 1 trial of CD40 agonist, Flt3L, and chemotherapy in breast cancer
Phase 1 trial of CD40 agonist, Flt3L, and chemotherapy in breast cancer Summary: Triple negative breast cancer (TNBC) is associated with more aggressive disease compared to other subtypes of breast cancer, with a median survival of less than 18 months for a patient diagnosed with metastatic disease. Despite the success of immune checkpoint inhibitors in […]
Sangeetha Reddy, MD, MSCI
University of Texas Southwestern Medical Center
Breast Cancer
A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination with Balstilimab in Patients with Metastatic Triple Negative Breast Cancer with expansion cohort in PD-L1 negative TNBC
A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination with Balstilimab in Patients with Metastatic Triple Negative Breast Cancer with expansion cohort in PD-L1 negative TNBC Summary: Triple negative breast cancer (TNBC) accounts for 15-20% of all breast cancers and it is highly aggressive, accounting for a disproportionate amount of metastatic […]
Yuan Yuan, MD, PhD
Cedars-Sinai Medical Center
Prostate Cancer
Clinical Trial of Androgen Deprivation Therapy and Copanlisib in High-Risk Prostate Cancer Patients with PTEN Loss Prior to Radical Prostatectomy
Clinical Trial of Androgen Deprivation Therapy and Copanlisib in High-Risk Prostate Cancer Patients with PTEN Loss Prior to Radical Prostatectomy Summary: Prostate cancer is the most common cancer in men and is the second leading cause of cancer death in men. It is characterized by dependence on the androgen receptor and activation of PI3K signaling […]
Dana Rathkopf, MD
Memorial Sloan Kettering Cancer Center
Brain Cancer
Evaluation of next-gen CAR-T cells targeting EGFRvIII and EGFR for GBM
Evaluation of next-gen CAR-T cells targeting EGFRvIII and EGFR for GBM Summary: Glioblastoma (GBM) is a deadly brain cancer with limited treatment options. Standard of care treatment is surgery followed by radiation and treatment with temozolomide, a chemotherapy. Standard of care has not changed in 15 years and despite treatment, most patients relapse in eight […]
Marcela Maus, MD, PhD
Massachusetts General Hospital Cancer Center
Blood Cancer
Enhancing the metabolic function of CAR T cells for lymphoma
Enhancing the metabolic function of CAR T cells for lymphoma Summary: CAR T-cell therapy has changed the treatment paradigms of relapsed diffuse large B-cell lymphoma (DLBCL) by demonstrating long term durability in approximately 40% of treated patients. CAR T-cell therapy is when a patient’s own T-cells (white blood cells that kill cancer cells) are collected […]
Gunjan Shah, MD
Memorial Sloan Kettering Cancer Center
Brain Cancer
Phase I/II Study of Pamiparib (BGB-290) with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations
Phase I/II Study of Pamiparib (BGB-290) with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations Summary: IDH1/2 mutations are commonly found in adult gliomas. Gliomas with these mutations are thought to have a better prognosis than patients without the IDH1/2 mutations, but nearly all patients will eventually recur, and thus better options are needed. A recent […]
Ranjit Bindra, MD, PhD
Yale University
Head/Neck Cancer
A randomized phase 2 study of local ablation with stereotactic body radiotherapy (SBRT) for patients with oligometastatic adenoid cystic carcinoma (ACC)
A randomized phase 2 study of local ablation with stereotactic body radiotherapy (SBRT) for patients with oligometastatic adenoid cystic carcinoma (ACC) Summary: Adenoid cystic carcinoma (ACC) is a rare type of salivary gland tumor. Despite upfront aggressive treatment with surgery, radiation therapy, and/or chemotherapy, approximately 50% of patients develop distance metastases, and up to a […]
Jonathan Schoenfeld, MD, MPhil, MPH
Dana-Farber Cancer Institute
Thyroid Cancer
Targeted Therapy Combined with Pembrolizumab in Anaplastic Thyroid Cancer: Two Phase II Clinical Trials
Targeted Therapy Combined with Pembrolizumab in Anaplastic Thyroid Cancer: Two Phase II Clinical Trials Summary: Anaplastic thyroid cancer (ATC) is a rare thyroid cancer representing less than 2% of all thyroid cancers. However, it is one of the most lethal human malignancies with a historical median survival of 3 months after diagnosis. Recent advances in […]
Mark Zafereo, MD, FACS
MD Anderson Cancer Center